Veterans Affairs data-based study finds that changing from MDI to DPI is linked to greater healthcare use, though the veteran ...

After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has advised ...

Flovent HFA had long been the most prescribed controller inhaler for young children with asthma. After it was removed from the market in January 2024, GSK partnered with Prasco Laboratories to ...

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for children.

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for ...

Asthma inhaler access dropped from nearly 41% to nearly 35% between 2021 and 2023 among patients 18 and younger prescribed Flovent (fluticasone), researchers found.

Mayes said GlaxoSmithKline raised prices “aggressively’’ on Flovent since it was first introduced in 2000 as a dry powder inhaler and four years later as a prescription metered-dose inhaler.